Key HighlightsCandel Therapeutics (NASDAQ:CADL) was trading down 39.21% at USD 5.10 in pre-market on Friday, November 13, 2026, after moving its planned prostate cancer FDA filing to mid-2027.Vir Biotechnology (NASDAQ:VIR) was down 14.85% at USD 10.32, a pullback after Phase 3 hepatitisDeltadata, although no …
Key HighlightsMoleculin Biotech (NASDAQ:MBRX) was trading down 10.63% at USD 7.20 in pre-market on Friday, November 13, 2026, nine days after interim data showed a 43% complete remission rate in one annamycin arm.BoneBiologics(NASDAQ:BBLG) was down 10.0% at USD 0.3601, about 74.6% below the USD …
Key HighlightsLakewood-Amedex Biotherapeutics (NASDAQ:LABT) was trading down 6.82% at USD 0.3347 in pre-market on Friday, November 13, 2026, after a sharp rise that followed aRedemptionannounced on November 5.The company redeemed all 127,097 Series C convertiblePreferred Sharesfor USD 1,270,970 in cash, about USD 10.00 a …
LifeMD describes itself as a virtual primary care and pharmacy company serving more than 200 conditions, including weight management and hormone therapy. Selling andMarketingexpense fell 34% from the second quarter to USD 18.5 million, which helped narrow the adjusted EBITDA loss to about USD …
Reported net income of USD 87 million, a 37% margin, includes a USD 14.4 million contingent consideration revaluation gain and a USD 1.4 million earnout revaluation gain, so about USD 71 million excludes them (calculated). Net interest expense fell to USD 25 million from …
On November 10, 2026, Merlin announced a USD 8.9 million task order for the next phase of the C-130J autonomy program with U.S. Special Operations Command, and on November 11 it said it was selected for the first phase of an Africa Command casualty …
On September 24, 2026, Mobix Labs (NASDAQ:MOBX) said it expected revenue for the fiscal quarter ended September 30, 2026 to exceed USD 1.6 million, about double the prior quarter, with a substantial sequential rise in grossMarginfrom higher volumes and mix. The figure is the …
The latest verified catalyst is the quarter ended September 30, 2026. Net sales rose 35% to USD 994.4 million, net earnings fell 32% to USD 30.3 million and adjusted EBITDA rose 31% to USD 136.2 million. GrossMarginwas 20.7%, down 160 basis points. Data Centers …
The first prespecified interim analysis covered 45 randomized patients with relapsed or refractory AML receiving annamycin with cytarabine. Complete remission rates were 43% and 36% in the two annamycin arms against 12% in the placebo arm. The company said it saw no signs, symptoms …
The company sells wellness products through a direct-selling model, with members as its main customers. Third-quarter revenue of USD 7.6 million was down 20% on the year, and nine-month revenue was USD 24.4 million, down 19% from USD 30.0 million. The operating loss narrowed …